GlassScriptPhysician profile
Lance L Lane
NPI 1023088655
$11,829.84
in general payments reported to CMS, 2019-2025
44 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,477 · 2022: $2,083 · 2023: $3,460 · 2024: $3,654 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,231 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,231.22 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,719.79 | 2021-2025 | |
| Lilly USA, LLC | $1,467.79 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,264.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $990.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $816.64 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $712.29 | 2021-2025 | Austedo Xr, Ajovy, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $375.97 | 2022 | |
| Tris Pharma INC | $328.18 | 2023-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $305.63 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $268.67 | 2023-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $191.97 | 2022-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.93 | 2022-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $161.39 | 2023-2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $135.51 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.31 | 2023-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $123.92 | 2024-2025 | Rexulti, Vyepti |
| Idorsia Pharmaceuticals US INC | $118.11 | 2022-2024 | Quviviq |
| Optinose US, INC. | $114.02 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.78 | 2021-2024 | Jardiance |
| Astellas Pharma US INC | $101.16 | 2023-2025 | Veozah |
| Antares Pharma, INC. | $96.18 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Janssen Pharmaceuticals, INC | $95.54 | 2022-2025 | Spravato |
| Abbott Laboratories | $91.19 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $84.38 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $82.59 | 2024-2025 | Tlando |
| Axsome Therapeutics, INC. | $81.09 | 2023-2024 | Sunosi, Auvelity |
| Novartis Pharmaceuticals Corporation | $79.87 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.32 | 2021-2023 | Trintellix |
| Halozyme INC | $60.26 | 2023 | |
| Exact Sciences Corporation | $58.55 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mylan Specialty L.P. | $58.46 | 2022-2023 | Yupelri |
| Neurocrine Biosciences, INC. | $57.40 | 2024-2025 | Ingrezza |
| Radius Health, INC. | $49.42 | 2024-2025 | Tymlos |
| Aimmune Therapeutics, INC. | $40.81 | 2024-2025 | Zenpep |
| Sunovion Pharmaceuticals INC. | $37.88 | 2022 | |
| Azurity Pharmaceuticals, INC. | $34.01 | 2024-2025 | Horizant, Azmiro |
| Edwards Lifesciences Corporation | $31.54 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Otsuka America Pharmaceutical, INC. | $31.38 | 2024 | Rexulti |
| Impel Pharmaceuticals INC. | $20.51 | 2023 | Trudhesa |
| Sanofi Pasteur INC. | $19.33 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.83 | 2024 | Strensiq |
| Nestle Healthcare Nutrition INC. | $16.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.30 | 2024 | Eliquis |
| Arbor Pharmaceuticals, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.